← Back to Search

Cell Therapy

1 for Cardiomyopathy (CAuSMIc II Trial)

Phase 2
Waitlist Available
Research Sponsored by Mytogen, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights

CAuSMIc II Trial Summary

The purpose of this study is to evaluate the safety and effectiveness of injecting myoblasts (grown from your own skeletal muscle), using a catheter device, directly into the damaged heart muscle for treatment of severe heart failure.

Eligible Conditions
  • Cardiomyopathy

CAuSMIc II Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Kansas City Cardiomyopathy Questionnaire
Secondary outcome measures
Cardiovascular mortality

CAuSMIc II Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: 1Experimental Treatment1 Intervention
myoblast
Group II: 2Placebo Group1 Intervention
sham injection procedure

Find a Location

Who is running the clinical trial?

Mytogen, Inc.Lead Sponsor
~10 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top